GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK PLC said Friday that a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival.

GSK Phase 3 trial for Jemperli endometrial cancer treatment met primary endpoint

Intel

Paramount Global

T. Rowe Price Group

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

Intel is back on my stock watch list. Down 45% this year and I currently own 182 shares and want to get to 200 shares. United Parcel Service stock is staying on my dividend stock watch list. This is even after the stock price of UPS has gone up $15 per share since my last article or 9%.

Dividend Stock Watch List: Lanny's December 2022 Edition

GSK plc (NYSE:GSK ) 5th Annual Evercore ISI HealthCONx Conference 2022 November 30, 2022 8:00 AM ET Company Participants Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Kimberly Smith - Head of Research & Development Conference Call Participants Umer Raffat - Evercore ISI . Jessica Hui - Evercore ISI Umer Raffat Well, thank you all for joining us on our day two of the conference.

GSK plc (GSK) Presents at 5th Annual Evercore ISI HealthCONx Conference 2022

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK PLC GSK, +0.87% said Tuesday that it has started the withdrawal process of the U.S. marketing authorization for its Blenrep treatment, following the request of the country's Food and Drug Administration.

GSK to withdraw Blenrep's U.S. marketing authorization after FDA request

GSK PLC (LSE:GSK, NYSE:GSK) has started for withdrawal process for US marketing authorisation for Blenrep following a request of the US Food and Drug Administration (FDA).  The request followed the previously announced outcome of the DREAMM-3 phase III trial which failed to meet FDA requirements wiping around £1.7bn of the FTSE 100 listed group's share price.

GSK halts US marketing process for Blenrep after recent disappointing trial data

GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, representing the latest in a series of setbacks for the British drugmaker's oncology business.

GSK to stop selling blood cancer drug Blenrep in United States

GSK plc (NYSE:GSK ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 4:45 AM ET Company Participants David Redfern - Chief Strategy Officer Conference Call Participants Peter Welford - Jefferies Peter Welford Thank you all very much. We've got a bit of room around the front that's why - over the head if people want to move around.

GSK plc (GSK) 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)

Pfizer

Pfizer Inc late on Wednesday received the U.S. Food and Drug Administration's nod for its respiratory syncytial virus (RSV) vaccine for older adults, nearly a month after GSK's shot was approved by the regulator.

Factbox: US FDA approves Pfizer RSV vaccine a month after greenlighting GSK shot

GSK: Step-Changing for Growth

Shares of GSK GSK, -3.85% fell nearly 4% in London as UBS downgraded the pharmaceutical giant to sell from neutral. “We see two factors posing risks to the earnings base longer term – blockbuster vaccine Shingrix will exhaust its catch-up patient pool in the U.S. around '27 and HIV product dolutegravir faces patent expiry at the same time.

GSK shares lower as UBS downgrades pharma giant to sell

GSK PLC (LSE:GSK, NYSE:GSK) shares have been slapped with a 'sell' rating by UBS, which downgraded its recommendation as it sees two big long-term risks ahead.  Admittedly, the risks are all the way out in 2027, when the Swiss bank worries that blockbuster shingles vaccine Shingrix will "exhaust its catch-up patient pool in the US" and HIV product dolutegravir faces patent expiry.

GSK slapped with 'sell' rating over long-term risks

British pharmaceutical company GSK has seen an 8% price rise since I wrote about it a little over a month ago. What has driven this? Its upgraded earnings outlook and approvals for its treatments have likely buoyed the stock, adding to the already improving market mood.

GSK: Near-Term Upside

Britain's GSK said on Friday it will limit the use of its ovarian cancer treatment Zejula in the United States, to patients with some genetic anomalies when given as a second option to keep their cancer at bay.

GSK to limit U.S. use of ovarian cancer drug to some populations

GSK PLC (LSE:GSK, NYSE:GSK) said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers, remains unchanged.

GSK second-line applications of new cancer drug will be restricted

Sanofi

Sanofi and GSK's next-generation COVID-19 booster vaccine Vid P revtyn ® Beta approv ed by the European Commission

Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK , after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

Sanofi, GSK score late win with EU COVID booster approval

Cardinal Health

Cincinnati Financial

Cisco Systems

Diageo

Fulton Financial

Genuine Parts

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Philip Morris

Schlumberger

TotalEnergies SE

We received $801.63 in October dividend income. This was the first quarter we received a dividend from Vanguard's S&P 500 Index fund (VOO).

Bert's October Dividend Income Summary

City broker Shore Capital remained upbeat on the prospects for shares in GSK PLC (LSE:GSK, NYSE:GSK) in spite of the failure of a key clinical trial for a new bone marrow cancer drug. It repeated its ‘buy' recommendation and said stock in the pharma giant was materially undervalued compared with its peers.

GSK slide wipes £2.5bn off its market value, but for one broker this puts the stock in bargain basement territory

Almost £1.7bn was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) in opening deals after the drug developer revealed a late-stage study failed to meet its main goal. Blenrep was deemed no better than the current standard of care in helping people with hard-to-treat multiple myeloma, a type of bone marrow cancer.

GSK loses almost £1.7bn value after drug trial failure

GSK's blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday.

GSK's blood cancer drug fails main goal of trial, shares fall

Viatris

The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial) and Universal Health Services ( UHS , Financial), a reduction to its holding in Vertex Pharmaceuticals Inc. ( VRTX , Financial), a new holding in GSK PLC ( LSE:GSK , Financial) and a boost to its holding in DexCom ( DXCM , Financial).

Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter

GSK's experimental fluoroquinolone antibiotic gepotidacin ended its trial early due to its success in treating uncomplicated urinary tract infections (UTIs), the pharma announced this week. Deutsche Bank says that while a new antibiotic won't set investors' pulses racing, it might be a nice add-on.

GSK's new antibiotic a handy add-on, suggests Deutsche Bank

GSK PLC (LSE:GSK, NYSE:GSK) said it was calling an early halt to trials of a new treatment for uncomplicated urinary tract infection (uUTI) because it has already proved its efficacy. An Independent Data Monitoring Committee (IDMC) recommended stopping the EAGLE-2 and EAGLE-3 phase III trials for gepotidacin as they had already met the primary endpoint without any safety concerns.

GSK to submit urinary infection treatment for approval after trial success

GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.

GSK vaccine for older adults granted FDA priority review

News for GlaxoSmithKline Stock (GSK)